NCT02482324 is a Phase 1 clinical trial of ALZT-OP1a in Healthy Volunteers, sponsored by AZTherapies, Inc..

Who is sponsoring NCT02482324?

NCT02482324 is sponsored by AZTherapies, Inc..

What drugs are being tested in NCT02482324?

Interventions in NCT02482324: ALZT-OP1a, ALZT-OP1b, Dry Powder Inhaler.

What condition does NCT02482324 study?

NCT02482324 studies Healthy Volunteers.

Is NCT02482324 still recruiting?

NCT02482324 is currently completed. Last updated 20 July 2015.

Last reviewed 2015-07-20 · How we verify

NCT02482324

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I, Randomized, Open-Labeled Pharmacokinetic Study of ALZT-OP1 in Normal Healthy Volunteers

Completed Phase 1 Last updated 20 July 2015

What this trial tests

Phase 1 trial testing ALZT-OP1a in Healthy Volunteers in 26 participants. Completed in 1 July 2015.

Timeline

1 June 2015

Primary endpoint
1 July 2015

1 July 2015

Quick facts

Lead sponsor	AZTherapies, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Enrollment	26
Start date	1 June 2015
Primary completion	1 July 2015
Estimated completion	1 July 2015
Sites	1 location across United States

Drugs / interventions tested

ALZT-OP1a — full drug profile →
ALZT-OP1b — full drug profile →
Dry Powder Inhaler

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

AZTherapies, Inc. — full company profile →

Who can join

Adults 55 to 75, any sex, with Healthy Volunteers. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Non-compartmental plasma pharmacokinetics for ALZT-OP1a and ALZT-OP1b
Time frame: T=0 to 6 hours (0, 5, 10, 15, 30, 60, 120, 240, and 360 minutes)
* AUC (0-∞) (area under the curve from 0 to infinity) * AUC (0-t) (area under the curve from 0 to t hours where t is the last measured concentration * AUCPLASMA/AUCCSF (ratio at 5 min, 30 min, 2 hr and 4 hours) * CL/F (apparent total body clearance) * Cmax (maximum plasma concentration observed) * T ½ (half life) * Tmax (sampling time at which Cmax occurred) * Vd/F (apparent volume of distribution

Sponsor's own description

This is an open-labeled, cross-over design, pharmacokinetic study, to determine the pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a and ALZT-OP1b, in both plasma and CSF, following co-administration of the active compounds, in healthy volunteers, aged 55-75, and in good general health.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The roles of inflammation and immune mechanisms in Alzheimer's disease.
Van Eldik LJ, Carrillo MC, Cole PE, Feuerbach D, et al · · 2016 · cited 154× · PMID 29067297 · DOI 10.1016/j.trci.2016.05.001
Repurposed agents in the Alzheimer's disease drug development pipeline.
Bauzon J, Lee G, Cummings J. · · 2020 · cited 46× · PMID 32807237 · DOI 10.1186/s13195-020-00662-x
Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China.
Cao Y, Yu F, Lyu Y, Lu X. · · 2022 · cited 16× · PMID 36457865 · DOI 10.3389/fneur.2022.1034243

Verify or expand the search:

Other trials of ALZT-OP1a

Trials testing the same drug.

NCT02547818 — Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease · Phase 3 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other AZTherapies, Inc. trials

Trials by the same sponsor.

NCT04428775 — A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease · Phase 2 · terminated
NCT04570644 — Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers · Phase 1 · completed
NCT02547818 — Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02482324 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AZTherapies, Inc.
Last refreshed: 20 July 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02482324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing